Comparative Pharmacology
Head-to-head clinical analysis: MYDRIACYL versus PAREDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYDRIACYL versus PAREDRINE.
MYDRIACYL vs PAREDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticholinergic agent that blocks muscarinic receptors in the eye, causing mydriasis and cycloplegia.
Paredrine (hydroxyamphetamine) is a sympathomimetic amine that acts as an indirect-acting adrenergic agonist, displacing norepinephrine from presynaptic nerve terminals and inhibiting its reuptake, leading to activation of alpha- and beta-adrenergic receptors.
For refraction: 1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated every 5-10 minutes for up to 3 doses; for cycloplegia: 1-2 drops of 1% solution topically, repeated once after 5 minutes.
5-10 mg intramuscularly (IM) or subcutaneously (SC) every 30-60 minutes as needed; intravenous (IV) dose: 2-5 mg every 5-10 minutes, not to exceed 50 mg total.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in adults; prolonged in elderly and patients with hepatic impairment
Terminal elimination half-life is 12-15 hours; may be prolonged in renal impairment.
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 30%)
Renal (approximately 80% as unchanged drug and metabolites); biliary/fecal (minor, <10%).
Category C
Category C
Mydriatic
Mydriatic